Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05434858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imagery as Biomarker of Gout

Study acronym: TIGER
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 21
    • Primary completion date changed from estimate of Sep 9, 2024 to Aug 31, 2024
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Sep 1, 2024 to Sep 9, 2024
    • Study completion date: Sep 1, 2029 to Sep 9, 2029
    • Start date changed from estimate of Sep 1, 2022 to Sep 9, 2022
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to determine whether MSU crystal deposits visualized on ultrasound and/or DECT are associated with the development of symptomatic gout (according to ACR 2015 / EULAR criteria) over 5 years in hyperuricemic individuals.
Trial Details
NCT Number NCT05434858
Lead Sponsor Lille Catholic University
Collaborators: Auckland University
Conditions
(from sponsor)		 Hyperuricemia
Related terms Gout, Hyperuricemia
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov